Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CPA3 | P15088 | 1/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19994458 | 0.83 | LMNA (0.45) | CYP2D6KDM4ECYP3A4CYP1A2CYP2C19 | |
| SCHEMBL10973243 | 0.83 | KMT2A (0.47) | ALDH1A1HSD17B10KDM4EPOLBHPGD | |
| SCHEMBL29000169 | 0.82 | KMT2A (0.50) | ALDH1A1CYP2D6HSD17B10KDM4ETP53 | |
| SCHEMBL28786000 | 0.79 | MGLL (0.38) | ALDH1A1HSD17B10HPGDALOX12L3MBTL1 | |
| SCHEMBL721638 | 0.79 | KMT2A (0.37) | ALDH1A1ALOX12MAPK1L3MBTL1MAPT | |
| SCHEMBL28286235 | 0.75 | LMNA (0.41) | ALDH1A1MAPTMEN1KMT2AGSK3A | |
| SCHEMBL381291 | 0.74 | KMT2A (0.46) | ALDH1A1HPGDMAPK1MEN1KMT2A | |
| SCHEMBL9562580 | 0.74 | MGLL (0.46) | ALDH1A1TP53HPGDALOX12MAPK1 | |
| SCHEMBL8871482 | 0.73 | ALDH1A1 (0.41) | ALDH1A1CYP2D6HSD17B10CYP3A4CYP1A2 | |
| SCHEMBL8871478 | 0.73 | ALDH1A1 (0.41) | ALDH1A1CYP2D6HSD17B10CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140363491-A1 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO., LTD. (JP) | 2014-12-11 | — | — | US | disclosed |
| EP-1863448-B1 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-8758810-B2 | Liposome compositions | MEBIOPHARM CO., LTD. (JP) | 2014-06-24 | — | — | US | disclosed |
| CN-101351225-B | Tumor-targeted nanodelivery systems to improve early mri detection of cancer | UNIV GEORGETOWN | 2013-09-25 | — | — | CN | disclosed |
| US-20110081404-A1 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO., LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
| US-7829113-B2 | comprising one or more phosphatidylcholines, an N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug, cholesterol; cancer treatment | MEBIOPHARM CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| CN-101351225-A | Tumor-targeted nanodelivery systems to improve early mri detection of cancer | GEORGETOWN UNVERSITY (US) | 2009-01-21 | — | — | CN | disclosed |
| WO-2008030818-A2 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO., LTD. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20060222696-A1 | comprising one or more phosphatidylcholines, an N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug, cholesterol; cancer treatment | MEBIOPHARM CO., LTD. (JP) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060222696-A1 | comprising one or more phosphatidylcholines, an N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug, cholesterol; cancer treatment | PHOSPHO1, SGMS2, SGMS1 | ALDH1A1 3056/4885CYP2D6 2593/4885HSD17B10 587/4885 |
| US-20140363491-A1 | NOVEL LIPOSOME COMPOSITIONS | PHOSPHO1, LIPA, LYPLAL1 | ALDH1A1 4667/4885CYP2D6 2562/4885HSD17B10 2042/4885 |
| US-20110081404-A1 | NOVEL LIPOSOME COMPOSITIONS | PHOSPHO1, LIPA, LYPLAL1 | ALDH1A1 4667/4885CYP2D6 2562/4885HSD17B10 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.